These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

205 related items for PubMed ID: 9737829

  • 1. A retrospective chart review of uncontrolled use of metformin as an add-on therapy in type 2 diabetes.
    Johnson M, Krosnick A, Carson P, McDade AM, Laraway K.
    Clin Ther; 1998; 20(4):691-8. PubMed ID: 9737829
    [Abstract] [Full Text] [Related]

  • 2. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
    Ann Intern Med; 1998 Feb 01; 128(3):165-75. PubMed ID: 9454524
    [Abstract] [Full Text] [Related]

  • 3. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
    Hershon KS, Hershon PM.
    Endocr Pract; 2000 Feb 01; 6(1):20-5. PubMed ID: 11419922
    [Abstract] [Full Text] [Related]

  • 4. An overview of metformin in the treatment of type 2 diabetes mellitus.
    Davidson MB, Peters AL.
    Am J Med; 1997 Jan 01; 102(1):99-110. PubMed ID: 9209206
    [Abstract] [Full Text] [Related]

  • 5. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.
    Turner RC, Cull CA, Frighi V, Holman RR.
    JAMA; 1999 Jun 02; 281(21):2005-12. PubMed ID: 10359389
    [Abstract] [Full Text] [Related]

  • 6. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
    Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, Maffioli P.
    Metabolism; 2014 Jul 02; 63(7):957-67. PubMed ID: 24874591
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V, NovoLog Mix-vs.-Exenatide Study Group.
    Curr Med Res Opin; 2009 Jan 02; 25(1):65-75. PubMed ID: 19210140
    [Abstract] [Full Text] [Related]

  • 8. Treatment of non-insulin-dependent diabetes mellitus with metformin.
    Guthrie R.
    J Am Board Fam Pract; 1997 Jan 02; 10(3):213-21. PubMed ID: 9159660
    [Abstract] [Full Text] [Related]

  • 9. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
    Avilés-Santa L, Sinding J, Raskin P.
    Ann Intern Med; 1999 Aug 03; 131(3):182-8. PubMed ID: 10428734
    [Abstract] [Full Text] [Related]

  • 10. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T, Fövényi J, Faludi P, Han J, Macconell L, Wille S, Kiljanski J.
    Clin Ther; 2012 Jun 03; 34(6):1301-13. PubMed ID: 22608106
    [Abstract] [Full Text] [Related]

  • 11. Metformin: a new treatment option for non-insulin-dependent diabetes mellitus.
    Goo AK, Carson DS, Bjelajac A.
    J Fam Pract; 1996 Jun 03; 42(6):612-8. PubMed ID: 8656173
    [Abstract] [Full Text] [Related]

  • 12. Oral Hypoglycemic Agents Added to Insulin Monotherapy for Type 2 Diabetes.
    Vos RC, Rutten GEHM.
    JAMA; 2017 Oct 17; 318(15):1489-1490. PubMed ID: 29049639
    [Abstract] [Full Text] [Related]

  • 13. Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.
    Fanghänel G, Sánchez-Reyes L, Trujillo C, Sotres D, Espinosa-Campos J.
    Diabetes Care; 1996 Nov 17; 19(11):1185-9. PubMed ID: 8908377
    [Abstract] [Full Text] [Related]

  • 14. Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.
    Riedel AA, Heien H, Wogen J, Plauschinat CA.
    Pharmacotherapy; 2007 Aug 17; 27(8):1102-10. PubMed ID: 17655510
    [Abstract] [Full Text] [Related]

  • 15. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M, Bursey D.
    Pediatrics; 2001 Apr 17; 107(4):E55. PubMed ID: 11335776
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparative Effectiveness of Second-Line Agents for the Treatment of Diabetes Type 2 in Preventing Kidney Function Decline.
    Hung AM, Roumie CL, Greevy RA, Grijalva CG, Liu X, Murff HJ, Ikizler TA, Griffin MR.
    Clin J Am Soc Nephrol; 2016 Dec 07; 11(12):2177-2185. PubMed ID: 27827311
    [Abstract] [Full Text] [Related]

  • 18. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF.
    Metabolism; 2009 Aug 07; 58(8):1059-66. PubMed ID: 19394976
    [Abstract] [Full Text] [Related]

  • 19. Retrospective comparison of voglibose or acarbose as an add-on therapy to sulfonylureas in Western Indian patients with uncontrolled overweight/obese type 2 diabetes.
    Talaviya PA, Saboo BD, Dodiya HG, Rao SK, Joshi SR, Modh VB, Ghadiya SV.
    Diabetes Metab Syndr; 2016 Aug 07; 10(2):88-91. PubMed ID: 26777258
    [Abstract] [Full Text] [Related]

  • 20. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.
    Bowker SL, Majumdar SR, Veugelers P, Johnson JA.
    Diabetes Care; 2006 Feb 07; 29(2):254-8. PubMed ID: 16443869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.